Skip to main content
Clinical Trials/CTRI/2021/11/038177
CTRI/2021/11/038177
Not yet recruiting
Phase 4

Safety and efficacy of Atropine 0.01% and 0.05% in prevention of the progression of Myopia in Indian children

Dr Siddharam S Janti0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: H521- Myopia
Sponsor
Dr Siddharam S Janti
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Siddharam S Janti

Eligibility Criteria

Inclusion Criteria

  • 1 )Age of 5 to 16 years
  • 2 ) Myopia â?? 1D to \-6 D
  • 3 )Annual myopic progression of greater than 0\.5 D

Exclusion Criteria

  • â??Refractive Myopia
  • â??Astigmatism \>\= 1\.5 D
  • â??Amblyopia
  • â??Prior intraocular surgery
  • â??Allergy to atropine eye drops
  • â??Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome
  • â??History of cardiac or significant respiratory diseases
  • â??Lack of consent for participating in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials